Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf, Takashi Seto, Ji‐Youn Han, +29

New England Journal of Medicine

Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, +42

New England Journal of Medicine

<i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation

Ken Takezawa, Valentina Pirazzoli, Maria E. Arcila, +13

Cancer Discovery

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma, +27

Cancer Discovery

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Juliann Chmielecki, Jasmine Foo, Geoffrey R. Oxnard, +18

Science Translational Medicine

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i>

Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila, +21

Proceedings of the National Academy of Sciences

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip, +27

New England Journal of Medicine

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

Vivek Subbiah, Jürgen Wolf, Bhavana Konda, +12

The Lancet Oncology

Thyroid TumoursMedicineMetronomic TherapyPathologyTumour-agnostic Efficacy +7

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer

Katsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki, +12

Journal of Thoracic Oncology

MedicineCancer Cell BiologyPathologyPhase Ii StudyCancer Biology +6

Characteristics of Lung Cancers Harboring <i>NRAS</i> Mutations

Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila, +20

Clinical Cancer Research